InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (10 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
10
T+90 hit rate
100%
T+90 mean return
+10.0%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by YANCOPOULOS GEORGE, Président et Directeur Scientifique. Insider active across 1 company, notably Regeneron Pharmaceuticals, INC.. Cumulatively, 18 disclosures have been published. Breakdown: 0 buy · 10 sells. Total volume traded: €89.9m. History available since 12 January 2021. The latest transaction was filed on 10 June 2024 (Don). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations18 total
75,799 shares0Common StockSEC:0001883850-24-000033:0
▼
111 shares@ US$965.690.0% of flowCommon StockSEC:0001968202-24-000093:0
▼
907 shares@ US$967.400.4% of flowCommon StockSEC:0001968202-24-000094:0
36,296 shares0Common StockSEC:0001883850-24-000013:0
▼
16,848 shares@ US$900.006.0% of flowCommon StockSEC:0001883850-24-000012:0
◇
172,723 shares@ US$399.6628.0% of flowCommon StockSEC:0001968202-24-000068:0
▼
16,848 shares@ US$900.006.0% of flowCommon StockSEC:0001883850-24-000007:0
25,155 sharesCommon StockSEC:0001883850-23-000095:0
▼
254 shares@ US$800.590.1% of flowCommon StockSEC:0001883850-23-000062:0
▼
13,189 shares@ US$800.084.3% of flowCommon StockSEC:0001883850-23-000044:0
◇
239,063 shares@ US$179.1316.5% of flowCommon StockSEC:0001883850-21-000034
◇
239,063 shares@ US$179.130.052% mcap29.8% of flowCommon StockSEC:0001883850-21-000034:0
▼
773 shares@ US$625.000.0006% mcap0.3% of flowCommon StockSEC:0001708138-21-000055:0
▼
773 shares@ US$625.000.2% of flowCommon StockSEC:0001708138-21-000055
▼
50,000 shares@ US$600.060.035% mcap19.9% of flowCommon StockSEC:0001708138-21-000044:0
▼
50,000 shares@ US$600.0611.0% of flowCommon StockSEC:0001708138-21-000044
82,108 shares0Common StockSEC:0001708138-21-000026:0
82,108 shares0Common StockSEC:0001708138-21-000026
18 of 18 declarations
About YANCOPOULOS GEORGE
George Yancopoulos is the President and Chief Scientific Officer at REGENERON PHARMACEUTICALS, INC. He is responsible for the company's scientific direction, overseeing the research and development of new treatments. His expertise in biotechnology and pharmacology is essential in guiding research initiatives. He plays a key role in developing scientific strategies and product innovation.
